Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue that has been studied extensively for its effects on body composition and visceral adipose tissue. Clinical research has primarily focused on people with HIV-associated lipodystrophy, where tesamorelin has demonstrated reductions in visceral abdominal fat.


Research indicates that tesamorelin stimulates the body's natural growth hormone pathway, which can influence body composition and metabolic markers. A recent 2026 meta-analysis of randomized controlled trials found reductions in visceral adipose tissue, trunk fat, hepatic fat, and waist circumference, while lean body mass increased in the studied population.


Because tesamorelin affects the growth hormone and IGF-1 pathways, understanding its safety profile and appropriate clinical context is important. Research has reported potential adverse effects including injection-site reactions, joint or muscle discomfort, and changes in IGF-1 levels.
https://zycarepeptides.com/product/tesamorelin/
https://zycarepeptides.com/